Citation Impact
Citing Papers
Nucleic acid detection with CRISPR-Cas13a/C2c2
2017 StandoutScience
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
2018
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer
2018
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study
2008
Co-incidence of RCC-susceptibility polymorphisms with HIF cis-acting sequences supports a pathway tuning model of cancer
2019 StandoutNobel
The RNA-binding Protein HuR Opposes the Repression of ERBB-2 Gene Expression by MicroRNA miR-331-3p in Prostate Cancer Cells
2011
Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice
2020 StandoutNobel
Cell-free circulating tumor DNA in cancer
2016
Beyond Antibodies: The DARPin® Drug Platform
2020
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
De novo design of immunoglobulin-like domains
2022 StandoutNobel
Effect of physical exercise on muscle mass and strength in cancer patients during treatment—A systematic review
2013
Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss
2014
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
2015
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
2018
Development of the EORTC QLQ-CAX24, A Questionnaire for Cancer Patients With Cachexia
2016
Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force
2014
A view on drug resistance in cancer
2019 StandoutNature
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
2016
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Neutrophils in cancer: prognostic role and therapeutic strategies
2017
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Limits to Personalized Cancer Medicine
2016
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia
2014
O-Pair Search with MetaMorpheus for O-glycopeptide characterization
2020 StandoutNobel
The Molecular Signatures Database Hallmark Gene Set Collection
2015 Standout
Nutrition and physical activity guidelines for cancer survivors
2012 Standout
Antisense therapeutics in oncology: current status
2014
Prostate cancer
2015
Hepatocellular carcinoma
2021 Standout
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Definition and classification of cancer cachexia: an international consensus
2011 Standout
Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes
2015
Cancer stem cells revisited
2017 Standout
The multilayered complexity of ceRNA crosstalk and competition
2014 StandoutNature
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
2016
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
2017
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Delivery technologies for cancer immunotherapy
2019 Standout
Cancer-associated cachexia
2018 Standout
Multimodal biomedical AI
2022 Standout
Large Oncosomes in Human Prostate Cancer Tissues and in the Circulation of Mice with Metastatic Disease
2012
Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer
2016
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
2015
Revealing the human mucinome
2022 StandoutNobel
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
2017
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
2015
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Sarcopenia
2019 Standout
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
2015 Nature
The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity
2017 StandoutNobel
In vitro-engineered non-antibody protein therapeutics
2017
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
2016
Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling
2017 StandoutNatureNobel
De novo design of buttressed loops for sculpting protein functions
2024 StandoutNobel
Food connections: A qualitative exploratory study of weight- and eating-related distress in families affected by advanced cancer
2015
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
Neutrophils in cancer: neutral no more
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
Endogenous microRNA sponges: evidence and controversy
2016 Standout
Receptor subtype discrimination using extensive shape complementary designed interfaces
2019 StandoutNobel
Malnutrition, fatigue, frailty, vulnerability, sarcopenia and cachexia
2012
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
2017
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
TIMER2.0 for analysis of tumor-infiltrating immune cells
2020 Standout
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial
2014
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Insights into Cytokine–Receptor Interactions from Cytokine Engineering
2014
Combination therapy in combating cancer
2017 Standout
Wound Healing: A Cellular Perspective
2018 Standout
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
2013 Standout
Psychosocial impact of cancer cachexia
2014
Practical multimodal care for cancer cachexia
2016
C‐reactive protein, symptoms and activity of daily living in patients with advanced cancer receiving palliative care
2017
Constraints in cancer evolution
2017
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
2014 Standout
The Tumor Microenvironment Innately Modulates Cancer Progression
2019 Standout
Effects of interleukin-2 in immunostimulation and immunosuppression
2019
The applicability of a weight loss grading system in cancer cachexia: a longitudinal analysis
2017
Characterization of DNA Methylation in Circulating Tumor Cells
2015
The Androgen Receptor in Health and Disease
2012
Recent Advances in Glycoproteomic Analysis by Mass Spectrometry
2019
Works of Aurelius Omlin being referenced
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
2013
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer
2013
Psychosocial Effects of Cancer Cachexia: A Systematic Literature Search and Qualitative Analysis
2012
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
2014
Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents
2013
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone
2013
Evolving classification systems for cancer cachexia: ready for clinical practice?
2010
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
2012
Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS
2018
Cancer cachexia: A systematic literature review of items and domains associated with involuntary weight loss in cancer
2011
The changing therapeutic landscape of castration-resistant prostate cancer
2011
Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways
2013
Tumor clone dynamics in lethal prostate cancer
2014
Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case–control study
2013
Simple prognostic score for metastatic castration‐resistant prostate cancer with incorporation of neutrophil‐to‐lymphocyte ratio
2014
Final results of the phase I trial of niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor incorporating proof of concept biomarker studies and expansion cohorts involving BRCA1/2 mutation carriers, sporadic ovarian, and castration resistant prostate cancer (CRPC).
2013
Comprehensive cancer cachexia staging and its impact in the outpatient oncology setting: A phase II study
2009
Abstract B25: First-in-human Phase I study to evaluate MP0250, a DARPin blocking HGF and VEGF, in patients with advanced solid tumors
2015
Circulating Tumor Cells: A Multifunctional Biomarker
2014
First-in-class phase I study evaluating MP0250, a VEGF and HGF neutralizing DARPIN molecule, in patients with advanced solid tumors.
2018
Interim results from the completed first-in-human phase I dose escalation study evaluating MP0250, a multi-DARPin® blocking HGF and VEGF, in patients with advanced solid tumors
2016
Secondary causes of cancer-related anorexia: Recognition in daily practice by a novel checklist, a pilot study
2007
Abstract OT1-03-02: MP0274-CP101: A phase 1, first-in-human, single-arm, multi-center, open-label, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors
2018